Bulk Inquiry
Netupitant
- Ro 67-31898- Soluble in 0.1N HCl(aq) and DMSO
- MF: C30H32F6N4O
- MW: 578.59
Description
Highly selective NK 1 receptor antagonist. Approved drug in combination with Palonosetron (clinically and pharmacologically distinct 5-HT3 receptor antagonist) indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV).
More Information
| Parent CAS No. | 290297-26-6 |
|---|---|
| Chemical Name | 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-o-tolylpyridin-3-yl)propanamide |
| SMILES | C1C(C(F)(F)F)=CC(C(C)(C)C(=O)N(C)C2C=NC(N3CCN(C)CC3)=CC=2C2C(C)=CC=CC=2)=CC=1C(F)(F)F |
| MFCD | MFCD25976831 |
| InChi | InChI=1S/C30H32F6N4O/c1-19-8-6-7-9-23(19)24-17-26(40-12-10-38(4)11-13-40)37-18-25(24)39(5)27(41)28(2,3)20-14-21(29(31,32)33)16-22(15-20)30(34,35)36/h6-9,14-18H,10-13H2,1-5H3 |
| InChiKey | WAXQNWCZJDTGBU-UHFFFAOYSA-N |
| CID | 6451149 |
| Short Description | NK1 antagonist |
References
- T. Hoffmann et al. Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1362-5.
- P.J. Hesketh et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.... Ann Oncol. 2014 Jul;25(7):1340-6.
- M. Stathis et al. Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol. 2012 Aug 15;689(1-3):25-30.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1119 | GR 159897 |
From $143.00 |
| 1486 | Aprepitant |
From $88.00 |
| 1533 | Osanetant |
From $209.00 |
| 1618 | Orvepitant maleate |
From $126.50 |
| 1901 | Casopitant mesylate |
From $137.50 |
Other Categories
Are you sure you would like to remove this item from the shopping cart?
This item is a part of the approved quote. Removing it will remove all quote items from the cart.


